Literature DB >> 2384119

Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat.

W Couet1, J Girault, F Latrille, C Salvadori, J B Fourtillan.   

Abstract

This study was conducted to determine kinetic profiles of the antidepressant tianeptine and its main metabolite (named MC5) in plasma, blood and brain after single (10 mg.kg-1) and chronic (10 mg.kg-1.day-1 and 2 x 10 mg.kg-1.day-1 for 15 days) intraperitoneal administration in Wistar rats. In plasma, tianeptine and MC5 reached a peak very quickly (5 and 15 min post administration respectively). Following the peak, disappearance of tianeptine was faster than that of MC5 with terminal half-lives close to 2.5 and 6.5 h respectively. During chronic treatment, accumulation of tianeptine was negligible, that of MC5 was slight as indicated by accumulation ratios equal to 1.28 (once daily administration) and 1.73 (twice daily administration). Tianeptine and MC5 rapidly appeared in brain tissue but at concentrations less than those observed in plasma. Peak concentrations of tianeptine in brain were higher than those of MC5. A very low penetration of tianeptine and MC5 into erythrocytes was observed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384119     DOI: 10.1007/BF03190130

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design.

Authors:  C Hansch; J P Björkroth; A Leo
Journal:  J Pharm Sci       Date:  1987-09       Impact factor: 3.534

Review 2.  Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials.

Authors:  R Defrance; C Marey; A Kamoun
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

3.  Ion-pair extraction and high-performance liquid chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues.

Authors:  G Nicot; G Lachatre; C Gonnet; J Mallon; E Mocaer
Journal:  J Chromatogr       Date:  1986-08-22

4.  Tianeptine and amitriptyline. Controlled double-blind trial in depressed alcoholic patients.

Authors:  H Lôo; R Malka; R Defrance; D Barrucand; J Y Benard; H Niox-Rivière; A Raab; A Sarda; G Vachonfrance; A Kamoun
Journal:  Neuropsychobiology       Date:  1988       Impact factor: 2.328

Review 5.  Neurochemical profile of tianeptine, a new antidepressant drug.

Authors:  G Kato; A F Weitsch
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

6.  Pharmacological antidepressive effects and tianeptine-induced 5-HT uptake increase.

Authors:  E Mocaër; M C Rettori; A Kamoun
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

7.  Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies.

Authors:  P Baumann; J M Gaillard; M Jonzier-Perey; C Gerber; C Bouras
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Tianeptine, a selective enhancer of serotonin uptake in rat brain.

Authors:  T Mennini; E Mocaer; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

  8 in total
  6 in total

Review 1.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

2.  The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor.

Authors:  Benjamin Adam Samuels; Katherine M Nautiyal; Andrew C Kruegel; Marjorie R Levinstein; Valerie M Magalong; Madalee M Gassaway; Steven G Grinnell; Jaena Han; Michael A Ansonoff; John E Pintar; Jonathan A Javitch; Dalibor Sames; René Hen
Journal:  Neuropsychopharmacology       Date:  2017-03-17       Impact factor: 7.853

3.  Chronic antidepressant treatment impairs the acquisition of fear extinction.

Authors:  Nesha S Burghardt; Torfi Sigurdsson; Jack M Gorman; Bruce S McEwen; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2012-12-20       Impact factor: 13.382

4.  Effects of tianeptine on stress-induced behavioural deficits and 5-HT dependent behaviour.

Authors:  P S Whitton; G S Sarna; K P Datla; G Curzon
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist.

Authors:  M M Gassaway; M-L Rives; A C Kruegel; J A Javitch; D Sames
Journal:  Transl Psychiatry       Date:  2014-07-15       Impact factor: 6.222

6.  Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method.

Authors:  Małgorzata Szafarz; Agnieszka Wencel; Krzysztof Pociecha; Filip A Fedak; Piotr Wlaź; Elżbieta Wyska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-12       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.